The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response
Year: 2007
Type: review
Abstract: The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.
Authors: K M Giacomini, C M Brett, R B Altman, N L Benowitz, M E Dolan, D A Flockhart, J A Johnson, D F Hayes, T Klein, R M Krauss, D L Kroetz, H L McLeod, A T Nguyen, M J Ratain, M V Relling, V Reus, D M Roden, C A Schaefer, A R Shuldiner, T Skaar, K Tantisira, R F Tyndale, L Wang, R M Weinshilboum, S T Weiss, I Zineh
Institutions: University of California, San Francisco, Stanford Medicine, University of Chicago, Indiana University School of Medicine, University of Florida, University of Michigan, U-M Rogel Cancer Center, University of North Carolina at Chapel Hill, St. Jude Children's Research Hospital, Vanderbilt University, Kaiser Permanente, University of Maryland, Baltimore, Brigham and Women's Hospital, University of Toronto, Mayo Clinic
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
Awards: G1036496709, G1124536103, Pharmacogenomics of Arrhythmia Therapy, G1498580612, G1701057896, G187421119, Pharmacogenetics of Asthma Treatment, G2075386466, The PharmGKB: Catalyzing Research in Pharmacogenetics, Pharmacogenomics and Risk of Cardiovascular Disease, Functional Polymorphism Analysis in Drug Pathways, PharmGKB: pharmacogenomics knowledge for precision medicine, Pharmacogenomic Evaluation of Antihypertensive Responses, Pharmacogenetics of Phase II Drug Metabolizing Enzymes, Pharmacogenetics of Phase II Drug Metabolizing Enzymes, G4277768125, Pharmacogenomics of Membrane Transporters, G466213475, Pharmacogenomics and Risk of Cardiovascular Disease, G489144377, G5342604401, G553328940, Pharmacogenetics Research Network and Knowledge Base, G6512022131, PAAR-Pharmacogenomics of Anticancer Agents Research Group, Pharmacogenomics of Arrhythmia Therapy, Pharmacogenetics of Nicotine Addiction Treatment, Pharmacogenomics of CVD risk Reduction, G8515188616, Pharmacogenetics of Membrane Transporters
OpenAlex ID: W2040550914